# Sources — Rachel Carson

> **SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD**

Accessed November 5, 2026. The canonical source metadata and claim links are in `case.json`.

## Historical evidence

1. National Park Service. "Rachel Carson." Supports her birth in Springdale, Pennsylvania, on May 27, 1907; her work at the Bureau of Fisheries and as editor-in-chief of Fish and Wildlife Service publications; her 1963 testimony before the Senate Committee on Commerce; and her death at home in Silver Spring, Maryland, on April 14, 1964. Its bibliography cites the New York Times obituary headed "Rachel Carson Dies of Cancer; 'Silent Spring' Author Was 56." https://www.nps.gov/people/rachel-carson.htm
2. Rachel Carson Council. "About Rachel Carson." Supports her birth on May 27, 1907, on a farm in Springdale; her career as writer, editor, and finally editor-in-chief at the Fish and Wildlife Service; *Under the Sea Wind* (November 1941) and *The Sea Around Us*; *Silent Spring* (1962); "learning that she had breast cancer in 1960"; and her death at home in Silver Spring on April 14, 1964. https://rachelcarsoncouncil.org/about-rcc/about-rachel-carson/
3. Science History Institute. "Rachel Carson" (scientific biography). Supports her hiring as a "junior aquatic biologist" in 1936; her resignation in 1952 to write full time; *Silent Spring* (1962); "In 1960, she underwent a radical mastectomy to remove tumors in her left breast"; "Within months of the operation, cancer had spread to her ribs and she began radiation treatment"; and testimony before two Congressional committees. https://www.sciencehistory.org/education/scientific-biographies/rachel-carson/
4. "Carson, Rachel (1907–1964)." *Women in World History: A Biographical Encyclopedia* (Gale), on Encyclopedia.com. Supports her birth date and place; the 1960 diagnosis and surgery that April; her working through "a catalogue of illnesses," flu, a sinus infection, heart trouble, arthritis, and an ulcer; that she told her publisher it was arthritis and only a few friends knew the truth; the June 4, 1963 testimony; and her death of cancer at home in Silver Spring on April 14, 1964. https://encyclopedia.com/women/encyclopedias-almanacs-transcripts-and-maps/carson-rachel-1907-1964
5. Stevens A. Review of *Rachel Carson: Witness for Nature* by Linda Lear. *The Trumpeter* 1998. Summarizes the standard biography: after a biopsy she asked if it was cancer "and was told it was not, a lie on the part of the surgeon, never forgiven by the patient"; a radical mastectomy followed by radiation; spread to lymph nodes, bones, and liver with more radiation and hormone treatment; and that she described her disability as "arthritis." https://www.trumpeter.athabascau.ca/index.php/trumpet/article/download/164/197?inline=1
6. "Call for a Cure." *Seattle Weekly*, October 9, 2006. Supports two lumps in her left breast in early 1960; that her surgeon did not tell her she had cancer even after the radical mastectomy, nor when later swelling showed spread; that he told her she had "a condition bordering on malignancy"; and that in a 1961 survey 90 percent of surgeons said they would do the same. https://www.seattleweekly.com/?p=78526
7. Lear L, ed. *Lost Woods: The Discovered Writing of Rachel Carson* (Beacon Press, 1998): letter to Dr. George Crile, Jr., with the editor's headnote, in an online transcription. The headnote calls Crile, of the Cleveland Clinic, "her cancer surgeon and friend," says she was "having to fight the medical profession to tell her the truth about her own illness," and that she hid her cancer from all but a handful of friends. The letter, early in 1963, reports angina diagnosed by a cardiologist, diseased nodes above the left collarbone under radiation, and an eroded shoulder bone, and asks for his honest assessment. The letter is summarized, not quoted. https://publicism.info/environment/woods/30.html
8. Griswold E. "How 'Silent Spring' Ignited the Environmental Movement." *New York Times Magazine*, September 21, 2012, read in a reprint PDF. Supports the June 4, 1963 testimony when she was 56 and dying of breast cancer, telling almost no one; the earlier radical mastectomy; pelvic fractures and a wig; publication of *Silent Spring* on September 27, 1962; and that, according to her assistant, her tone sharpened after she learned in 1960 that the cancer had spread. https://static1.squarespace.com/static/581a91969f7456744441bb8a/t/5e4494ac41cab754748bda1a/1581552814650/Sidebar+8-How+Silent+Spring+Ignited+a+Movement-+Griswold+NYT+9-2012.pdf
9. Rachel Carson Council. "Rachel Carson's Statement before Congress, 1963." The statement of June 4, 1963, to the Subcommittee on Reorganization and International Organizations of the Senate Committee on Government Operations. It says nothing about her health. https://rachelcarsoncouncil.org/about-rcc/about-rachel-carson/rachel-carsons-statement-before-congress-1963/
10. Maryland State Archives. Maryland Women's Hall of Fame, "Rachel Carson." Supports that she learned she had cancer while writing *Silent Spring* and died at her home in Silver Spring in 1964. https://msa.maryland.gov/msa/educ/exhibits/womenshall/html/carson.html
11. McCauley M. "Rachel Carson, Author of *Silent Spring*." Literary Ladies Guide. The only fetched source for the 1950 operation to remove "a benign tumor from her left breast." It dates a second operation to 1959, which every other source places in 1960. https://www.literaryladiesguide.com/author-biography/rachel-carson/
12. Oken D. "What to tell cancer patients. A study of medical attitudes." *JAMA* 1961;175:1120–8. PMID 13730593. Bibliographic record only. https://pubmed.ncbi.nlm.nih.gov/13730593/
13. Novack DH, et al. "Changes in physicians' attitudes toward telling the cancer patient." *JAMA* 1979;241(9):897–900. PMID 762865. Abstract: in 1961, 90 percent of responding physicians preferred not to tell a cancer patient the diagnosis; in 1977, 97 percent preferred to tell. https://pubmed.ncbi.nlm.nih.gov/762865/
14. Burstein HJ. "Fifty years of systemic therapy for breast cancer: from one size fits all to tailored therapy." *Am Soc Clin Oncol Educ Book* 2014:e1–3. PMID 24857085. Abstract only: the changes in breast cancer care are shown through her case. https://pubmed.ncbi.nlm.nih.gov/24857085/
15. HISTMED Master Roster v3. Internal project source. Its claims were provisional and were not treated as independent corroboration.

## Clinical guidance

1. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: Breast Cancer, Version 5.2025. Diagnostic workup, no staging scans for clinical stage I to II without symptoms, breast-conserving surgery or mastectomy, sentinel node biopsy, recurrence-score testing, radiation after breast conservation, endocrine therapy, and adjuvant CDK4/6 inhibitors. https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1419
2. American Medical Association. Code of Medical Ethics Opinion 2.1.3, "Withholding Information from Patients": withholding information without the patient's knowledge or consent is ethically unacceptable outside emergencies; information may be shared over time according to the patient's preferences, but disclosure must not be permanently delayed. https://code-medical-ethics.ama-assn.org/ethics-opinions/withholding-information-patients
3. Gilligan T, et al. "Patient-Clinician Communication: American Society of Clinical Oncology Consensus Guideline." *J Clin Oncol* 2017;35(31):3618–3632. PMID 28892432. https://pubmed.ncbi.nlm.nih.gov/28892432/
4. Bedrosian I, et al. "Germline Testing in Patients With Breast Cancer: ASCO-Society of Surgical Oncology Guideline." *J Clin Oncol* 2024. PMID 38175972. Testing for everyone diagnosed at 65 or younger. https://pubmed.ncbi.nlm.nih.gov/38175972/
5. Brackstone M, et al. "Management of the Axilla in Early-Stage Breast Cancer: Ontario Health (Cancer Care Ontario) and ASCO Guideline." *J Clin Oncol* 2021;39(27):3056–3082. PMID 34279999. No axillary dissection for one or two positive sentinel nodes with breast conservation and whole-breast radiation. https://pubmed.ncbi.nlm.nih.gov/34279999/
6. Burstein HJ, et al. "Adjuvant Endocrine Therapy for Women With Hormone Receptor-Positive Breast Cancer: ASCO Clinical Practice Guideline Focused Update." 2019. PMID 30523754. https://pubmed.ncbi.nlm.nih.gov/30523754/
7. Freedman RA, et al. "Optimal Adjuvant Chemotherapy and Targeted Therapy for Early Breast Cancer: Cyclin-Dependent Kinase 4 and 6 Inhibitors. ASCO Guideline Rapid Recommendation Update." *J Clin Oncol* 2024;42(18):2233–2235. PMID 38768407 (abstract read; it does not restate the recommendation, which rests on the NATALEE trial, PMID 38507751). https://pubmed.ncbi.nlm.nih.gov/38768407/
8. KISQALI (ribociclib) prescribing information, DailyMed (label published July 2026). Early breast cancer dose 400 mg daily for 21 of 28 days with an aromatase inhibitor for 3 years; ECG before starting (start only with QTcF below 450 ms) and at about day 14 of the first cycle; electrolytes at the start of the first 6 cycles; liver tests and blood counts every 2 weeks for 2 cycles, then at the start of the next 4 cycles; avoid QT-prolonging drugs. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=aaeaef94-f3f5-4367-8ea2-b181d7be2da8
9. Eisen A, et al. "Use of Adjuvant Bisphosphonates and Other Bone-Modifying Agents in Breast Cancer: ASCO-OH (CCO) Guideline Update." *J Clin Oncol* 2022;40(7):787–800. PMID 35041467. https://pubmed.ncbi.nlm.nih.gov/35041467/
10. Runowicz CD, et al. "American Cancer Society/American Society of Clinical Oncology Breast Cancer Survivorship Care Guideline." *CA Cancer J Clin* 2016;66(1):43–73. https://pubmed.ncbi.nlm.nih.gov/26641959/
11. Khatcheressian JL, et al. "Breast Cancer Follow-Up and Management After Primary Treatment: ASCO Clinical Practice Guideline Update." *J Clin Oncol* 2013;31(7):961–965. https://pubmed.ncbi.nlm.nih.gov/23129741/
12. CMID: Clinical Monitoring Intelligence Database (Aether Forge, 2026), breast cancer monograph. History and examination every 3 to 6 months for years 1 to 3; mammography after breast-conserving treatment; no routine blood tests, tumor markers, or distant imaging without symptoms; on an aromatase inhibitor, a baseline DXA repeated every 2 years, calcium and vitamin D, lipid monitoring, and joint-pain review; lymphedema assessment at every visit; distress screening; vasomotor and sexual symptom review; lifestyle counseling; a survivorship care plan. https://patrickrutledge.github.io/topthirty/
13. Chey WD, et al. "ACG Clinical Guideline: Treatment of Helicobacter pylori Infection." *Am J Gastroenterol* 2024. PMID 39626064. Bismuth quadruple therapy and a test of cure at least four weeks after antibiotics and two weeks off a proton pump inhibitor. https://pubmed.ncbi.nlm.nih.gov/39626064/
14. Kolasinski SL, et al. "2019 American College of Rheumatology/Arthritis Foundation Guideline for the Management of Osteoarthritis of the Hand, Hip, and Knee." PMID 31908149. https://pubmed.ncbi.nlm.nih.gov/31908149/
15. Chow AW, et al. "IDSA Clinical Practice Guideline for Acute Bacterial Rhinosinusitis in Children and Adults." *Clin Infect Dis* 2012. PMID 22438350. Used at the sick visit to judge the illness viral. https://pubmed.ncbi.nlm.nih.gov/22438350/
16. Medicare Preventive Services reference (Aether Forge, 2026), the preventive visit template (https://patrickrutledge.github.io/preventative_services/); U.S. Preventive Services Task Force A and B recommendations, colorectal cancer (2021), cervical cancer (2018), and statin use (2022) (https://www.uspreventiveservicestaskforce.org/uspstf/recommendation-topics/uspstf-a-and-b-recommendations); CDC hepatitis B screening, 2023 (https://pubmed.ncbi.nlm.nih.gov/36893044/), and the Adult Immunization Schedule by Age (https://www.cdc.gov/vaccines/hcp/imz-schedules/adult-age.html).

## Editorial resolutions

- **Teaching contrast: the 1960 nondisclosure.** The documented history is that her surgeon told her the tumor was not cancer, or "a condition bordering on malignancy," even after a radical mastectomy, and that she had to fight the medical profession for the truth (sources 5, 6, 7). This was the usual practice of the time: in a 1961 survey 90 percent of physicians preferred not to tell (sources 12 and 13). The synthetic episode is built as the opposite. At every result she is first asked what she wants to know, then told in person and in plain words, with a written copy and teach-back, and each treatment decision is hers, as AMA Opinion 2.1.3 and the ASCO communication guideline require. The surgeon of 1960 is not named in the record, and his words appear only as reported in the cited sources.
- **How she learned the truth.** The sources say that she learned later in 1960 that the cancer had spread, and that she sought the truth from another physician, George Crile Jr., whom her biographer calls her cancer surgeon and friend. No fetched source says who first told her, or exactly when, so the record does not say. A Wikipedia account citing the Lear biography says she learned in December 1960; it was not used as a source, and the timeline event is dated "Late 1960" (approximate).
- **The 1950 operation.** Only one popular biography (source 11) gives the 1950 removal of a benign left breast tumor, and the same source dates the second operation to 1959 rather than 1960. The claim is graded **D** with certainty probable. Another account found in search dated a first breast operation to 1946; it was not fetched and is not used. The synthetic history refers to a benign tumor removed "about ten years ago."
- **Arthritis and the other illnesses.** A reference biography lists flu, a sinus infection, heart trouble, arthritis, and an ulcer among the illnesses of the *Silent Spring* years, without dates, and a review of the standard biography says she called her disability "arthritis" to hide the cancer. So the modern knee osteoarthritis is synthetic and is not linked to that claim. The modern duodenal ulcer with *Helicobacter pylori* (resolved by the test of cure) and the sinus illness at the sick visit echo the documented ulcer and sinus infection, but are not linked to the claim, because the sources do not date them. Her documented angina and the later spread to nodes, bones, and liver are not used in the episode.
- **Privacy.** Her documented choice to hide her cancer from all but a few friends (source 7) is echoed as her own modern request that her diagnosis be shared only with the people she names. The intake documents show this as her present wish, not as the later historical fact.
- **Index age and dates.** She found lumps in her left breast in early 1960 and had a radical mastectomy in April 1960, at 52. The index visit on March 9, 2026 maps to March 9, 1960, before the operation, when she was 52, so the synthetic date of birth is May 27, 1973 (shift 66 years). The other visits (March 18, April 20, June 15, July 20, September 8, and October 13, 2026) map to the same days of 1960; the synthetic lumpectomy on April 6, 2026 maps to April 6, 1960, in the documented month of her operation, but no exact date of the 1960 operation is asserted. All visits fall within her lifetime and contradict no documented event.
- **Postmenopausal status.** Her menopausal status in 1960 is not given in any fetched source. A search summary of a 2014 ASCO article described her as premenopausal in April 1960; the full article could not be read. The synthetic episode makes her postmenopausal (menopause at 51), which decides the choice of letrozole without ovarian suppression. This is a synthetic choice for the teaching episode, not a historical assertion.
- **Stage and treatment.** Decided: early, curable disease in the modern episode, a deliberate counterfactual to her documented course. Clinical stage cT2 cN0, then pT2 pN1a(sn) with two of three sentinel nodes involved (anatomic stage IIB), grade 2, ER and PR positive, HER2 negative, Ki-67 22 percent, recurrence score 17. This was chosen to differ from the earlier breast cancer records (stage I to IIA node-negative disease, mastectomy, and survivorship care) and to teach the management of one or two positive sentinel nodes without axillary dissection, the omission of chemotherapy in a postmenopausal woman with one to three nodes and a recurrence score of 25 or less, and adjuvant ribociclib, for which stage II node-positive disease qualifies. She chose breast-conserving surgery over mastectomy; radiation to the whole breast and regional nodes; letrozole with ribociclib for three years; and adjuvant zoledronic acid. The 3-percentage-point benefit quoted for ribociclib comes from the NATALEE trial (three-year invasive disease-free survival about 90 versus 87 percent) and is a teaching approximation.
- **Sick visit.** An unscheduled sick visit on July 20, 2026 (true frame July 20, 1960) for acute viral rhinosinusitis on day 8 of the second ribociclib cycle, with expected grade 2 neutropenia and no fever. It teaches the distinction between viral and bacterial sinusitis, the febrile neutropenia warning, continuing ribociclib for grade 2 neutropenia, and avoiding QT-prolonging antibiotics. It does not insinuate an undocumented real diagnosis.
- **Preventive visit.** An adult preventive visit (age 53, so `preventive_adult`) on October 13, 2026 (true frame October 13, 1960). Synthetic judgment calls: the colonoscopy three years earlier and the cervical co-test two years earlier are recorded as normal history; hepatitis B, hepatitis C, and HIV screening are ordered with no results; the advance care planning names no real person as her health care agent, and its first instruction is that she always be told the truth.
- **Focused visits.** The four chronic-care follow-ups (diagnosis, two weeks after surgery, the start of adjuvant therapy, and the start of the fourth ribociclib cycle) are documented as focused visits on the NCCN breast cancer workup, the ribociclib prescribing information, the ASCO bone-modifying agent guideline, and the CMID breast cancer monograph. Each lists every item the protocol calls for at that point, including the items not indicated (breast MRI, staging scans, tumor markers). One protocol deviation is recorded: the ECG due at about day 14 of the first ribociclib cycle was missed while she was away for field work; it was done at the start of the second cycle (QTcF 426 ms), so no harm resulted, and the corrective action is recorded. The ribociclib blood tests between visits, done by the oncology team, are reported in prose (neutrophils 1.3 to 1.7, normal liver tests and electrolytes) and are not observations; the germline result, the recurrence score, and the urea breath test are also reported in prose or as procedures.
- **Consultation.** The breast surgical oncology referral and the consultation by Henrietta Solís-Abernathy, MD (a fictional consultant), on the day of the second visit, are **S**. The consultant answers the five referral questions with what the record shows happened afterwards: breast-conserving surgery, her choice after mastectomy was explained; no MRI or staging scans; sentinel node biopsy, with no axillary dissection for one or two positive nodes; germline testing before surgery (negative); and a recurrence score and multidisciplinary review, which led to radiation, letrozole, ribociclib, and zoledronic acid without chemotherapy. Medical and radiation oncology are unnamed teams.
- **Other clinicians and people.** No real relative, friend, editor, or physician is the source of any modern statement or decision. Crile is named only in a documented claim, as her biographer describes him. The physicians named in her 1963 letter are not named in the record. Her later public life and death are recorded only as claims.
- **Family history.** No family medical history is recorded; none was found in the fetched sources, and none is synthesized.
- **Presenting concern.** The intake documents list the presenting concern (PRB-003, a new left breast lump) rather than the breast cancer, which is recorded from the biopsy-results visit; the presenting concern is resolved, superseded by the diagnosis, from that visit on. The axillary nodal disease (PRB-006) is recorded from the post-operative visit.
- Carson died in 1964, so the recent-death review rule does not apply. Ordinary clinical, provenance, and safe-messaging reviews remain required.
